Reduced L-Carnitine Transport in Aortic Endothelial Cells from Spontaneously Hypertensive Rats

Rocio Salsoso¹, Enrique Guzmán-Gutiérrez¹, Pablo Arroyo¹, Carlos Salomón¹*, Sonia Zambrano², María Victoria Ruiz-Armenta², Antonio Jesús Blanca², Fabián Pardo¹, Andrea Leiva¹, Alfonso Mate², Luis Sobreíva¹,∗, Carmen María Vázquez²*

¹ Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, ² Department of Physiology, Faculty of Pharmacy, Universidad de Sevilla, Sevilla, Spain, ³ University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine and Biomedical Sciences, University of Queensland, Herston, Queensland, Australia

Abstract

Impaired L-carnitine uptake correlates with higher blood pressure in adult men, and L-carnitine restores endothelial function in aortic rings from spontaneously hypertensive rat (SHR). Thus, endothelial dysfunction in hypertension could result from lower L-carnitine transport in this cell type. L-Carnitine transport is mainly mediated by novel organic cation transporters 1 (Octn1, Na⁺-independent) and 2 (Octn2, Na⁺-dependent); however, their kinetic properties and potential consequences in hypertension are unknown. We hypothesize that L-carnitine transport kinetic properties will be altered in aortic endothelium from spontaneously hypertensive rats (SHR). L-Carnitine transport was measured at different extracellular pH (pH₅ 5.5–8.5) in the absence or presence of sodium in rat aortic endothelial cells (RAECs) from non-hypertensive Wistar-Kyoto (WKY) rats and SHR. Octn1 and Octn2 mRNA relative expression was also determined. Dilution of endothelium-intact or denuded aortic rings in response to calcitonine gene related peptide (CGRP, 0.1–100 nmol/L) was measured (myography) in the absence or presence of L-carnitine. Total L-carnitine transport was lower in cells from SHR compared with WKY rats, an effect due to reduced Na⁺-dependent (Na⁺ₐdep) compared with Na⁺-independent (Na⁺ₐindep) transport components. Saturable L-carnitine transport kinetics show maximal velocity (Vmax) without changes in apparent Km for Na⁺ₐindep transport in SHR compared with WKY rats. Total and Na⁺ₐdep Component of transport were increased, but Na⁺ₐindep Transport was reduced by extracellular alkalization in WKY rats. However, alkalization reduced total and Na⁺ₐindep transport in cells from SHR. Octn2 mRNA was higher than Octn-1 mRNA expression in cells from both conditions. Dilation of artery rings in response to CGRP was reduced in vessels from SHR compared with WKY rats. CGRP effect was endothelium-dependent and restored by L-carnitine. All together these results suggest that reduced L-carnitine transport (likely via Na⁺- dependent Octn2) could limit this compound’s potential beneficial effects in RAECs from SHR.

Introduction

Essential hypertension is characterized by high blood pressure without an identifiable primary cause [1,2]. Oral administration of L-carnitine, a natural amino acid compound, in patients with hypertension resulted in an improvement of arterial blood pressure, thus suggesting a beneficial vascular role for this compound in these subjects [3,4]. Along with the well-described role of L-carnitine on fatty acid mitochondrial metabolism [5,6], L-carnitine also increases the metabolic activity in human vascular endothelium [7,8], and improves the bioavailability of nitric oxide (NO) in rat aorta [9] and in fetal lamb pulmonary vasculature [10]. Other studies show that L-carnitine supplementation in healthy subjects improved postprandial flow-mediated dilation after a high-fat meal [11]. Taken together, all these findings suggest that the transport of L-carnitine into the endothelial cells could be an essential, limiting step of its potential beneficial biological effects in hypertension.

The uptake of L-carnitine is mediated by novel organic cation transporters (OCTNs) of which at least three isotypes (rOctn1, rOctn2 and rOctn3) are expressed in rats [12]. Octn1- an Octn3-mediated L-carnitine transport is independent of sodium (Na⁺) with apparent Michaelis-Menten (Km) values in the range of 2–200 µmol/L [13–15] and 3–6 µmol/L [16,17], respectively. On the contrary, Octn2-mediated transport is Na⁺-dependent with...
apparent $K_m$ between 2–20 μmol/L. [16,18–23]. Studies performed in spontaneously hypertensive rat (SHR) show that L-carnitine restores endothelial function in preparations of aortic rings [24,25], and ameliorates the high-systolic arterial blood pressure exhibited by hypertensive animals [5,8,26]. Interestingly, there are no reports addressing the properties of L-carnitine transport in endothelial cells from SHR. Thus, we hypothesize that the activity of OCTN1-mediated membrane transport of L-carnitine by the aortic endothelium is reduced in these hypertensive animals.

The results of this study show that aorta endothelial cells from SHR exhibit reduced maximal L-carnitine transport capacity compared with cells from non-hypertensive animals. Transport of L-carnitine was saturable and mediated by a larger Na$^+$-independent, Octn1-like compared with a Na$^+$-dependent, Octn2-like transport activity in these cells from SHR. However, similar Na$^+$-dependent and Na$^+$-independent transport components were found in non-hypertensive rats. It is suggested that the observed endothelial dysfunction in SHR could be due to reduced Na$^+$-dependent transport of L-carnitine, which could limit the potential beneficial effects of this compound in the endothelial function in hypertension.

**Methods**

**Ethics statement and animals**

This investigation strictly conforms to the principles outlined in the European Union Guidelines on the protection of animals used for scientific purposes (DIRECTIVE 2010/63/EU of the European Parliament and of the Council). Protocols were approved by the Committee on the Ethics of Animal Experiments of the University of Sevilla (Spain). Normotensive male Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR) aged 8 weeks were obtained from the French Animal Production Center, JANVIER S.A.S. (Saint Berthevin Cedex, France). Rats were housed at a temperature of 22–24°C in individual cages and freely fed (ad libitum) regular pellet diet (12 mm pellet, Harlan Laboratories, Indianapolis, USA) until they were 10 weeks of age (wa). They were divided into two groups of 15 animals each, i.e., WKY (control) and SHR (hypertensive) animals. Characterization of WKY rats and SHR in terms of the diastolic and systolic blood pressures and body weight was determined at arrival of the animals (8 wa) and at the moment of isolation of aorta endothelial cells (i.e., 10 wa) as reported [26]. Diastolic and systolic blood pressure values were not significantly different ($P>0.05$) at 8 wa (diastolic = 93 ± 3 mmHg, systolic = 123 ± 6 mmHg) compared with 10 wa (diastolic = 95 ± 2 mmHg, systolic = 124 ± 3 mmHg) in WKY rats. However, these parameters were elevated ($P<0.01$) in SHR at 8 wa (diastolic = 190 ± 2 mmHg, systolic = 233 ± 2 mmHg) and 10 wa (diastolic = 191 ± 2 mmHg, systolic = 231 ± 1 mmHg) compared with the corresponding systolic or diastolic values in WKY rats, but were not significantly different ($P>0.05$) between them in SHR.

**Cell culture**

Aortas from WKY rats and SHR aged 10 weeks were excised and placed in a petri dish containing phosphate-buffered saline (PBS) solution (mmol/L) NaCl 130, KCl 2.7, Na$_2$HPO$_4$ 0.8, KH$_2$PO$_4$ 1.4 (pH 7.4, 4°C). The tissue was rinsed by changing PBS until free of any visible blood, and the aorta was stripped of adventitia as reported [27]. Rat aorta endothelial cells (RAECs) were isolated by scraping of rat aortic lumen in the presence of medium 199 (M199) (Gibco Life Technologies, Carlsbad, CA, USA) containing 5 mmol/L D-glucose, 10% new born calf serum, 10% fetal calf serum (FCS) (Gibco), 3.2 mmol/L L-glutamine and 100 U/mL penicillin-streptomycin (primary culture medium, PCM) (Gibco), and cultured up to passage 3 (37°C, 5% CO$_2$). Twenty-four hours prior to experiments the incubation medium was replaced by M199 containing 2% sera after two rinses with 200 μL in PBS (37°C). Cells were used in passage 3 for most of the experiments. In addition, in some of transport assays confluent freshly isolated cells (i.e., passage 0) or cells in passages 1 or 2 in culture were also used.

**L-Carnitine transport**

Total transport of L-carnitine (TTC) was defined as the result of the sum of the Na$^+$-dependent (hereafter referred as $TTC_{Na^+dep}$) and Na$^+$-independent (hereafter referred as $TTC_{Na^+indep}$) components plus a nonsaturable, linear component of transport in the range of L-carnitine used in this study (hereafter referred as $m_1[Car]$, where $m_1$ corresponds to slopes of linear phases of TTC at each L-carnitine concentrations [Car]) [28]. The TTC (0–80 μmol/L L-carnitine, 3 μCi/mL L-[-$^3$H]carnitine (NEN, Dreieich, FRG), 30 seconds, 37°C) was measured as previously described for other amino acids in primary cultured endothelium [28]. Briefly, TTC assays were performed in a Na$^+$-containing Krebs ((mmol/L): NaCl 131, KCl 5.6, Na$_2$HCO$_3$ 25, NaH$_2$PO$_4$ 1, Hepes 20, D-glucose 5, CaCl$_2$ 2.5, MgCl$_2$ 1 (pH 7.4, 37°C)) or in Na$^+$-free Krebs solution (mmol/L): N-methyl-D-glucamine (NMDG) 120, KCl 5.6, Hepes 20, D-glucose 5, CaCl$_2$ 2.5, MgCl$_2$ 1 (pH 7.4, 37°C).

Initial rate for TTC, $TTC_{Na^+dep}$ and $TTC_{Na^+indep}$ components was derived from slopes of linear phases of 20 μmol/L L-carnitine transport. Values for L-carnitine transport were adjusted to the one phase exponential association equation considering the least squares fit:

$$v_i = V_m \cdot (1 - e^{-kt})$$

where $v_i$ is initial velocity, $V_m$ is mayor velocity at a given time ($t$) and L-carnitine concentration, and $k$ and $t$ are constants. Data for TTC, $TTC_{Na^+dep}$ and $TTC_{Na^+indep}$ components at initial rates (i.e., linear uptake up to 30 seconds) was adjusted to the Michaelis-Menten hyperbola plus a nonsaturable, linear component ($m_1[Car]$) as described [28]:

$$\frac{v}{V_{max}} = \frac{[Car]}{K_m + [Car]} + \left(m_1[Car]\right)$$

where $v$ is the initial reaction velocity relative to the maximal velocity ($V_{max}$) and apparent Michaelis-Menten parameter ($K_m$) of transport at a given L-carnitine concentration ([Car]), $m_1$ represents the slope of transport for the range of 0–80 μmol/L L-carnitine and $m_1[Car]$ is the nonsaturable, linear component of transport in the range of L-carnitine used in this study [28]. Each assay was run in duplicate with transport activity expressed as pmol/mg protein/minute.

After subtracting the $m_1[Car]$ component from TTC the remaining transport was defined as total overall saturable transport of L-carnitine (TSC). Transport in Na$^+$-free Krebs was considered as the Na$^+$-independent component of TSC: ($^{13}CS_{Na^+indep}$) and the Na$^+$-component ($^{13}CS_{Na^+dep}$) was derived from:

$$TSC_{Na^+dep} = TSC - TSC_{Na^+indep}$$
The kinetic parameters \( V_{\text{max}} \) and apparent \( K_m \) for the TSC, \( TSC^{\text{Na}^+} \text{dep} \) or \( TSC^{\text{Na}^+} \text{indep} \) components were estimated by fitting the data to the single Michaelis-Menten asymptotic hyperbola equation:

\[
\frac{V}{V_{\text{max}}} = \frac{[\text{Car}]}{K_m + [\text{Car}]}
\]

Cells were exposed to PCM 2% sera for a period of 2 hours before the transport assays were performed. Cell viability was assayed by Trypan blue exclusion and was not significantly altered (~96% of viable cells) in any experimental condition in this study. Rinsing the monolayers with ice-cold Krebs with or without Na+ terminated the tracer uptake. Radioactivity in formic acid cell digests was determined by liquid scintillation counting in an automated low activity liquid scintillation analyzer (Tri-Carb 2810TR, PerkinElmer, Santa Clara, CA, USA) with efficiency estimated by converting counts to disintegrations per minute (d.p.m.) [28]. Uptake of L-[3H]carnitine was corrected for its extracellular trapping by measuring the accumulation of the non-transportable D-[14C]mannitol for each sample analysed in the experiments. Isotopic counts for standards of L-[3H]carnitine and D-[14C]mannitol, respectively, were d.p.m. for standards of L-[3H]carnitine and D-[14C]mannitol, respectively.

The relative contribution of the hypertension exhibited by SHR to the saturable L-carnitine kinetic parameters (1/F) was estimated from the maximal transport capacity \( (V_{\text{max}}/K_m) \) values for TSC by:

\[
\frac{1}{[\text{WKY}]/[\text{SHR}]} = \frac{WKY V_{\text{max}}}{[\text{SHR} V_{\text{max}} / K_m]}
\]

where \( WKY V_{\text{max}} / [\text{WKY}]/[\text{SHR}] \) and \( V_{\text{max}} / K_m \) are the kinetic parameters for TSC in cells from WKY rats, and \( V_{\text{max}} / K_m \) are kinetic parameters of transport in cells from SHR. The relative contribution of the \( TSC^{\text{Na}^+} \text{dep} \) or \( TSC^{\text{Na}^+} \text{indep} \) components to TSC in SHR or WKY rats was estimated from:

\[
\frac{1}{TSC^{\text{Na}^+} / \text{SHR}} = \frac{TSC^{\text{Na}^+} \text{dep} / \text{SHR}}{TSC^{\text{Na}^+} \text{dep} / \text{WKY}}
\]

where \( X \) represents the \( TSC^{\text{Na}^+} \text{dep} / \text{SHR} \) or \( TSC^{\text{Na}^+} \text{dep} / \text{WKY} \) for the kinetics parameters \( V_{\text{max}} \) and \( K_m \) of transport compared with TSC values. The relative contribution of the \( TSC^{\text{Na}^+} \text{dep} \) transport compared with the \( TSC^{\text{Na}^+} \text{indep} \) component to L-carnitine transport in SHR or WKY rats was estimated from:

\[
\frac{1}{TSC^{\text{Na}^+} \text{dep} / \text{IWkY}} = \frac{Na^{+} \text{dep} K_m}{Na^{+} \text{indep} K_m}
\]

### Extracellular pH dependency
To assay the effect of extracellular pH (pH_{o}) on TSC, \( TSC^{\text{Na}^+} \text{dep} \) or \( TSC^{\text{Na}^+} \text{indep} \) components of L-carnitine transport (20 μmol/L L-carnitine, 3 μCi/mL L-[3H]carnitine, 30 seconds, 37°C) the cells were incubated in Na+-containing or Na+-free Krebs adjusted to a final pH, of 5.5, 6.5, 7.5 or 8.5 as described [20]. The pH_{o} in the Na+-containing Krebs solution was adjusted with 1 N HCl or 1 N NaOH, while the Na+-free Krebs solution was adjusted with 1 N HCl or 1 N KOH. The pH_{o} values were monitored with a pH-meter (Oakton Instrument, Vernon Hills, IL, USA) and tracer uptake was terminated as above.

### Isolation of total RNA and reverse transcription
Total RNA was isolated using the Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA quality and integrity were insured by gel visualization and spectrophotometric analysis (OD_{260/280}), and RNA concentration was determined at 260 nm. Aliquots (1 μg) of total RNA were reverse transcribed into cDNA as described [28].

### RT-PCR
Experiments were performed using a Light Cycler 480 Detection System (Roche Diagnostic, Barcelona, Spain) in a reaction mix containing 0.5 μmol/L primers and master mix provided in the brilliant SYBR green qPCR Master Mix (Stratagene, La Jolla, CA, USA). SecureStart Tag DNA polymerase was activated (15 minutes, 95°C), and assays included a 95°C denaturation (15 seconds), annealing (20 seconds) at 54°C, and extension (10 seconds) at 72°C (rOctn1, rOctn2 and GAPDH). Product melting temperature values were 86°C (rOctn1), 86°C (rOctn2) and 85°C (GAPDH). Oligonucleotide primers: rOctn1 (sense) 5′-TGATAGCTCTTCCTGCGGATTTG-3′, rOctn1 (anti-sense) 5′-AAGGAGCCACAGAGAAGCGCTAC-3′, rOctn2 (sense) 5′-AGGAGCCCATCACGACACCCACG-3′, rOctn2 (anti-sense) 5′-GACGAAAGGACGAGCAAGTGTGC-3′, GAPDH (sense) 5′-GGCAAGAGGTCATCTCAGCCG-3′, GAPDH (anti-sense) 5′-GGATGACCTTGCCACAGGCGTT-3′.

The relative mRNA level in each group was estimated from the 2^{-\Delta\Delta Ct} method [29]. Data were analyzed using the Light Cycler 480 SW 1.5 relative quantification (delta-delta-Ct) study software (Roche Diagnostic, Barcelona, Spain) and gene expression levels were normalized to GAPDH and given as relative fold change [30]. The GAPDH mRNA level was not significantly altered (P>0.05, n=13) in all experimental conditions used in this study (not shown).

### Rat aorta reactivity
Segments of 2–4 mm in length were dissected from rat aorta in cold (4°C) PBS solution. Vessel rings were mounted in a myograph (610M Multiwire Myograph System, Danish Myo Technology A/S, Denmark) for isometric force measurements in a Krebs physiological solution (mmol/L): NaCl 118.5, KCl 4.7, NaHCO_{3} 25, MgSO_{4} 1.2, KH_{2}PO_{4} 1.2, CaCl_{2} 2.5, D-glucose 5.5, 300 μmol/L L-arginine, pH 7.4). Artery rings were maintained at 37°C and constantly bubbled with a mixture of 95% O_{2}/5% CO_{2}. The optimal diameter for each vessel was adjusted through the determination of the maximal active response evoked by 62.5 μmol/L KCl [28]. Isometric force was measured in response to calcitonin gene related peptide (CGRP, 0.1–100 μmol/L, 5 minutes) (Peptides International, Inc., KY, USA) in 32.5 μmol/L KCl preconstricted vessels, in the absence or presence of 20 μmol/L L-carnitine (30 minutes). In some artery rings, the endothelium was removed by gentle abrasion of the intimal surface. Effective removal of this cell layer was determined by a reduction in the
vasodilatation to CGRP. Changes in isometric tension were recorded using the software LabChart (LabChart 7 for Windows, ADInstruments, Australia) coupled to a PowerLab (PowerLab 8/30 Data Acquisition System, ADInstruments, Australia). The tissue responses are as a percentage of maximal contraction induced by 62.5 mM KCl.

Statistical analysis

Values are mean ± SEM, where n indicates the number of different cell cultures (3–4 replicates). Data reported in this study describe a normal standard distribution and comparison between two or more than two groups were performed by means of Student’s unpaired t-test and analysis of variance (2-way ANOVA), respectively. If the ANOVA demonstrated a significant interaction between variables, post hoc analyses were performed by the multiple-comparison Bonferroni correction test. The statistical software GraphPad Instat 3.0b and Graphpad Prism 6.0d (GraphPad Software Inc., San Diego, CA, USA) were used for data analysis. *P<0.05 was considered statistically significant.

Results

Overall transport of L-carnitine

The TTC for 20 μmol/L L-carnitine was lower (44±8%) in RAECs from SHR compared with WKY rats (Fig. 1a). TTC exhibited a \( T^{+}T^{+}C^{+}Na_{dep} \) and a \( T^{+}T^{+}C^{+}Na_{indep} \) component in cells from both SHR and WKY rats. However, in cells from WKY rats the contribution of the \( T^{+}T^{+}C^{+}Na_{dep} \) (52±6%) and \( T^{+}T^{+}C^{+}Na_{indep} \) (60±7%) components to the TTC were similar (P>0.05), whereas, TTC in cells from SHR resulted from a major contribution of the \( T^{+}T^{+}C^{+}Na_{indep} \) (64±6%) compared with the \( T^{+}T^{+}C^{+}Na_{dep} \) (25±5%) component of transport (Fig. 1a). Cells in passage 0 (Fig. 1b), 1 (Fig. 1c) or 2 (Fig. 1d) exhibited similar changes in L-carnitine transport compared with cells in passage 3 (Fig. 1a).
The \( TT^+ \) was lineal up to 40 seconds incubation (Fig. 2a) with \( v_i \) values lower in SHR compared with WKY rats (Table 1). In cells from either SHR or WKY rats the \( v_i \) for the \( TT^+Na^+_\text{dep} \) compared with the corresponding \( TT^+Na^+_\text{indep} \) component was higher for 20 \( \mu \)mol/L L-carnitine transport. However, the difference between the \( v_i \) for the \( TT^+Na^+_\text{dep} \) compared with \( TT^+Na^+_\text{indep} \) component was higher (2.1 ± 0.3 fold) in cells from SHR compared with WKY rats (Fig. 2b).

L-Carnitine transport kinetics

The \( TT^+ \) was semisaturable in RAECs from either SHR or WKY rats (Fig. 3a,b). The \( K_D \) value for \( TT^+ \) was similar to that for the \( TT^+Na^+_\text{indep} \) component of transport in cells from WKY rats; however, the \( K_D \) for \( TT^+Na^+_\text{dep} \) transport in cells from these animals and all other \( K_D \) values in SHR were negligible (Table 1). The \( TT^+Na^+_\text{dep} \) and \( TT^+Na^+_\text{indep} \) components derived from \( TT^+ \) were saturable in both groups of cells. The Eadie-Hofstee plot of \( TT^+ \) data was best fitted by an exponential one phase decay equation resulting in a non-linear plot in cells from WKY rats (Fig. 3c).

However, the \( TT^+Na^+_\text{dep} \) and \( TT^+Na^+_\text{indep} \) components derived from \( TT^+ \) in WKY rats were linear (Fig. 3c), as were \( TT^+ \), \( TT^+Na^+_\text{dep} \) and \( TT^+Na^+_\text{indep} \) components of transport in SHR (Fig. 3d).

After subtracting the lineal, non-saturable component of transport data (in the range of concentrations used in this study), the saturable transport for each condition was obtained (Fig. 4a,b). Cells from SHR exhibit reduced \( TT^+Na^+_\text{dep} \) component derived from \( TT^+ \) transport in cells from these animals compared with WKY rats (Table 1). The \( V_{\text{max}} \) for the \( TT^+Na^+_\text{dep} \) but not for \( TT^+Na^+_\text{indep} \) components of transport was reduced in cells from SHR compared with the corresponding values in WKY rats. In addition, the \( V_{\text{max}} \) for the \( TT^+Na^+_\text{indep} \) component was higher than \( TT^+Na^+_\text{dep} \) component of transport only in SHR (Table 1). The Eadie-Hofstee plot of saturable transport data was lineal for all experimental conditions (Fig. 4c,d).

The \( V_{\text{max}}/K_m \) values for saturable transport and the \( Na^+_\text{dep} \) component were lower in SHR compared with WKY rats, and the value for the \( TT^+Na^+_\text{indep} \) component was lower than the \( TT^+Na^+_\text{dep} \) component of transport in cells from SHR or WKY rats (Table 1).

### Table 1. Kinetic parameters for transport of L-carnitine in rat aortic endothelial cells.

| L-Carnitine transport | WKY | SHR |
|----------------------|-----|-----|
| **TT^+** | | |
| \( v_i \) | 0.007 ± 0.0001 | 0.003 ± 0.0002 | 0.004 ± 0.0003† |
| \( K_D \) | 0.0016 ± 0.0002 | < 10\(^{-13}\) | < 10\(^{-13}\) |
| **TSC** | | |
| \( V_{\text{max}} \) | 0.84 ± 0.2 | 0.42 ± 0.06 | 0.46 ± 0.2 |
| \( K_m \) | 28 ± 9 | 46 ± 19 | 21 ± 4 |
| \( V_{\text{max}}/K_m \) | 0.030 ± 0.008 | 0.009 ± 0.002 | 0.022 ± 0.009† |

Total (TT^+) and saturable (TSC) transport of L-carnitine in rat aortic endothelial cells (RAECs) from normotensive (WKY) or spontaneously hypertensive (SHR) rats was described in Methods. A historical velocity \( (v) \) was measured for 20 \( \mu \)mol/L L-carnitine up to 30 seconds. \( v_i \), initial velocity (pmol/µg protein/second); \( V_{\text{max}} \), maximal velocity (pmol/µg protein/minute); \( K_m \), apparent Michaelis-Menten constant (µmol/L); \( V_{\text{max}}/K_m \), maximal transport capacity (pmol/µg protein/minute/µmol/L); \( K_D \), lineal, non-saturable transport in the range of L-carnitine concentrations used in this study (pmol/µg protein/minute/µmol/L).

* \( P < 0.05 \) versus corresponding values in WKY, † \( P < 0.05 \) versus corresponding values for \( Na^+_\text{dep} \) in SHR or WKY rats. Values are mean ± SEM (n = 15).

doi:10.1371/journal.pone.0090339.g002
Expression of rOctn1 and rOctn2 mRNA

The relative expression of rOctn2 was higher than rOctn1 mRNA in RAECs from SHR or WKY rats (Fig. 5). The relative mRNA expression of rOctn2 was largely lower in SHR when compared with WKY; however, no differences were found in mRNA expression of rOctn1 between cells from these animals.

Extracellular pH dependency on saturable L-carnitine transport

Overall transport of L-carnitine was higher at pH 8.5 compared with transport at pH 7.4, but it was unaltered by lower pH values in cells from WKY rats (Fig. 6a). The $^{22}\text{Na}^{+}_{\text{indep}}$ component of transport at pH 7.4 was higher than at pH 8.5, but lower than at acidic pH values. However, the $^{22}\text{Na}^{+}_{\text{dep}}$ component of transport at pH 7.4 was lower than at alkaline, but higher than at acidic pH values. The half-maximal stimulatory effect ($SE_{50}$) of a change in the pH on overall transport was higher than the $SE_{50}$ for $^{22}\text{Na}^{+}_{\text{indep}}$ ($~0.26$ pH units of difference) component (Table 2). A similar effect on $TSC$ was seen for the half-maximal inhibitory effect ($IE_{50}$) of a change in the pH on the $^{22}\text{Na}^{+}_{\text{dep}}$ ($~0.53$ pH units of difference) component of transport in cells from WKY rats (Table 2). In addition, the $SE_{50}$ for $^{22}\text{Na}^{+}_{\text{indep}}$ was significantly different from the $IE_{50}$ for $^{22}\text{Na}^{+}_{\text{indep}}$ values ($~0.24$ pH units of difference) in these cells.

In RAECs from SHR, the $TSC$ and the $^{22}\text{Na}^{+}_{\text{dep}}$ component of transport were lower at alkaline pH values compared with transport at pH 7.4 (Fig. 6b). However, the $^{22}\text{Na}^{+}_{\text{indep}}$ component of saturable transport was unaltered compared with values at pH 7.4 in these cell types. The $IE_{50}$ values for overall and the $^{22}\text{Na}^{+}_{\text{indep}}$ component of L-carnitine transport ($~0.05$ pH units of difference) were not significantly different in cells from SHR (Table 2). However, the alkalization required to reduce the overall transport in cells from SHR was higher ($~0.22$ pH units of difference) compared with the alkalization required to increase the transport in cells from WKY rats. In addition, the alkalization required to reduce the $^{22}\text{Na}^{+}_{\text{indep}}$ component of transport in cells from SHR was higher ($~0.93$ pH units of difference) compared with cells from WKY rats.

Rat aorta reactivity

CGRP caused dilation of preconstricted aortic rings in both group of animals (Fig. 6c). However, the half-maximal vasodilation
(EC50) caused by CGRP was lower in vessels from SHR (EC50 = 9.5 ± 0.3 nmol/L) compared with WKY (EC50 = 1.0 ± 0.2 nmol/L) rats. Supplementation with L-carnitine caused a reduction of the EC50 for CGRP in vessels from SHR (EC50 = 1.9 ± 0.3 nmol/L), but did not alter (P > 0.05) this parameter in vessels from WKY rats (EC50 = 0.9 ± 0.1 nmol/L). CGRP was ineffective in endothelium-denuded rat aortic rings (Fig. 6d).

Discussion

We have characterized the kinetics of L-carnitine transport in primary cultures of rat aortic endothelial cells (RAECs) from non-hypertensive WKY rats and contrasted this information with cells from spontaneously hypertensive rats (SHR). Total overall transport of L-carnitine (TTC) was mediated by Na+-dependent (TTCNa+dep) and Na+-independent (TTCNa+indep) transport components (0–80 μmol/L L-carnitine, 3 μCi/mL L-[3H]carnitine, 30 seconds, 37°C) in RAECs cultures from WKY rats (a) or SHR (b). The Eadie-Hofstee plots for transport data are shown for WKY rats (c) and SHR (d) from data in (a) and (b), respectively. Values are mean ± SEM (n = 15).
doi:10.1371/journal.pone.0090339.g004

Reduced L-Carnitine Transport in Hypertension

Figure 4. Saturable transport of L-carnitine kinetics. Total saturable transport of L-carnitine (Total), and the Na+-dependent (Na+dep) and Na+-independent (Na+indep) transport components (0–80 μmol/L L-carnitine, 3 μCi/mL L-[3H]carnitine, 30 seconds, 37°C) in RAECs cultures from WKY rats (a) or SHR (b). The Eadie-Hofstee plots for transport data are shown for WKY rats (c) and SHR (d) from data in (a) and (b), respectively. Values are mean ± SEM (n = 15).

Reduced L-Carnitine Transport in Hypertension

PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e90339
L-Carnitine transport in normotensive rats

Several reports describe that the natural amino acid L-carnitine could act by improving the high arterial blood pressure in patients with essential hypertension [3,4] and in animal models of hypertension [5,26]. These results complement the possibility that in hypertension the membrane transport of this amino acid is reduced, a phenomenon that is supported by studies showing a correlation between increased L-carnitine plasma level and higher blood pressure in adult men [31]. Plasma membrane transport of L-carnitine is mediated by OCTNs in mammalian cells, and the isotypes Octn1, Octn2 and Octn3 have been cloned from rats [16,18–22]. Octn2 is also expressed in other types of endothelial cells, including human heart and brain capillaries [23,40]; therefore Octn2 could also account for the Na+-dependent transport of L-carnitine in RAECs. Interestingly, since the plasma concentration of L-carnitine for WKY rats is reported as 20–36 μmol/L [41] it is likely that the lower affinity transport system Octn1 would play a preferential role compared with Octn2, which is likely to be saturated at physiological L-carnitine plasma concentrations, in maintaining the extracellular physiological concentrations of this amino acid in these animals.

In the present study, both Octn1 and Octn2 mRNA expression was detected in RAECs from WKY rats. Interestingly, Octn2 mRNA relative expression resulted to be ~3 fold higher compared with Octn1 mRNA in these cells. Since the relative contribution of the TSCNa⁺_dep component to the V_max/K_m for TSC was ~30%, it is likely that not more than ~10 fold change in Octn2 mRNA expression (estimated from the (Octn2 mRNA/Octn1 mRNA)/(1/TSCNa⁺/Na⁺_dep)F ratio) could sustain a TSCNa⁺_dep component for the TSC in RAECs. The remaining transport mediated via a TSCNa⁺_indop component (~73%) could represents the contribution of a Na⁺-independent transport activity derived from Octn1 in this cell type. Interestingly, since the contribution for the Na⁺-dependent Octn2 transport is reported as ~3 fold higher than the transport detected in the absence of extracellular Na⁺ in other cell types [42], an equivalent fractional contribution for these components to L-carnitine transport in RAECs from WKY rats could be expected. However, the latter seems unlikely in this cell type since the relative contribution of the TSCNa⁺_dep component to the V_max/K_m for TSC was ~30% (1/TSCNa⁺/Na⁺_dep)F = 0.3) compared with ~73% (1/TSCNa⁺/Na⁺_indop)F = 0.73) for the TSCNa⁺_indop component. Thus, contrasting with other cell types [35,42], these findings further support the possibility that the Na⁺_indop component predominates (~2.4 fold) compared with the Na⁺_dep component regarding their contribution to TSC. This could be interpreted as a major contribution of Octn1 compared with Octn2 to the saturable transport of L-carnitine in RAECs from WKY rats.

L-Carnitine transport in RAECs from WKY rats was also dependent on the H⁺_o, a characteristic well described for Octn1 [13,32] and Octn2 [43]. Our results show that TSC was increased by ~20% by alkalinization of the extracellular medium, an effect resulting from a combined increases in the TSCNa⁺_indop component (~58%) and decreases in the TSCNa⁺_dep component (~29%). This phenomenon could be due to a higher sensitivity to alkalinization of the TSCNa⁺_dep ([TSC SE50] = 26 units of pH, compared with the TSCNa⁺_indop ([TSC SE50] = 50 units of pH) components regarding the change seen in TSC. Based in these findings, a higher alkalinization-dependent increase in the TSC could be reached whether these two transport components were equally altered or whether the TSCNa⁺_indop component was unaltered by this environmental condition. Interestingly, the increase of TSC caused by a change of 0.6 units of pH, in RAECs was ~3.3 fold the increase reported for 150 μmol/L tetraethylammonium (TEA) uptake in response to a similar change in pH, units in HEK293 cells expressing the human OCTN1 form [13]. However,
contrasting with these results a larger increase in the pH, value (1 unit of pH) reduced overall transport of TEA in these cells [32]. Thus, it is likely that OCTNs-like transport is differentially responsive to the degree of alkalization reached in HEK293 cells. Interestingly, a change in $\Delta pH_0$, 0.4 units of pH, has been shown to increase the activity of other membrane transport systems, such as the sodium/proton exchanger isoform 1 in MDCK cells [44], suggesting that modulation of Octn1/2 by a similar change in the pHo in RAECs agrees with what is reported in other cell types. On the other hand, acidification of the extracellular pHo does not alter TSC, a net effect that results from a proportional reduced TSC, Na$^{+}$ dep and increased TSC, Na$^{+}$ indep transport components. Interestingly the effect of extracellular acidification was similar for both components, suggesting that these components are equally sensitive to acidification in RAECs from WKY rats. Thus, acidification and alkalization of extracellular medium results in a differential modulation of L-carnitine transport in RAECs from non-hypertensive rats.

Figure 6. Effect of extracellular pH on saturable transport of L-carnitine, and rat aorta reactivity. Total saturable transport of L-carnitine (Total), and the Na$^{+}$-dependent (Na$^{+}$ dep) and Na$^{+}$-independent (Na$^{+}$ indep) transport components (20 μmol/L L-carnitine, 3 μCi/mL L-[3H]carnitine, 30 seconds, 37°C) in RAECs cultures from WKY rats (a) or SHR (b) exposed to culture medium with the pH adjusted to different values. (c) Relaxation of 3.25 mmol/L KCl preconstricted endothelium-intact aortic vessel rings (With endothelium) from WKY rats or SHR in response to increasing concentrations of calcitonin gene related peptide (CGRP, 5 minutes), in the absence (-Car) or presence (+Car) of 20 μmol/L L-carnitine (30 minutes). (d) Relaxation of endothelium-denuded aortic vessel rings (Without endothelium) to CGRP as in (c). *P<0.05 versus all other values for the corresponding components. Values are mean ± SEM (n = 4–10).

doi:10.1371/journal.pone.0090339.g006

Effect of spontaneous hypertension on L-carnitine transport

Cells from SHR exhibit a semisaturable TTC unaffected by a lineal, non-saturable component in the range of L-carnitine concentrations used in this study. This data was best fitted to a first-order regression line in an Eadie-Hofstee plot, suggesting that one or more transport systems with apparent $K_m$ values in the same range could mediate L-carnitine transport in RAECs from SHR. The apparent $K_m$ values for L-carnitine transport by RAECs in SHR were similar to values detected in non-hypertensive rats, and within the range of the plasma L-carnitine concentration reported in SHR (21–41 μmol/L) [41]. Thus, L-carnitine transport via Octn1/2 could contribute to maintaining the physiological plasma concentration of this amino acid in SHR. Our results also show that TTC is mainly mediated by a $TTC Na^{+}$ indep (~75%) with a minor contribution of $TTC Na^{+}$ dep (~25%) components. These findings agree with those obtained by contrasting the relative $V_{max}/K_m$ for these components with that for TSC. Since
the relative contribution of the \( TSC^+Na^{+}_{dep} \) component is higher (\( \sim 75\% \)) \( (1/TSC/Na^{+}\text{total}F = 0.75) \) compared with the contribution accounted by the \( TSC^+Na^{+}_{indep} \) component (\( \sim 30\% \)) \( (1/TSC/Na^{+}\text{total}F = 0.30) \), and considering that similar findings were found for the \( i_1 \) values for these transport components, it is suggested that RAECs from SHR exhibit saturable transport of L-carnitine where the \( Na^+\)-independent transport predominates by \( \sim 2.5 \) fold compared with the \( Na^+\)-dependent. This result is \( \sim 2.1 \) fold higher compared with cells from non-hypertensive rats supporting the possibility that hypertension could associate with a higher fold requirement of \( Na^+\)-independent transport of L-carnitine via Octn1/2 activity in RAECs. Thus, it is likely that a deficiency in this component to the \( Na^+\)-dependent transport results in RAECs dysfunction in SHR. This would not be explained by a lower \( V_{\text{max}}/K_m \) of the \( TSC^+Na^{+}_{indep} \) component, since the relative contribution of this component to \( TSC \) in these cells was similar to that in cells from non-hypertensive rat \( (1/TSC/Na^{+}\text{total}F \text{ in WKY rats})/(1/TSC/Na^{+}\text{total}F \text{ in SHR} = 1.01) \). In addition, the relative contribution of the \( TSC^+Na^{+}_{dep} \) component compared with the \( TSC^+Na^{+}_{indep} \) component to \( TSC \) in SHR is also similar to non-hypertensive rats \( (1/Na^{+}\text{total}F/Na^{+}\text{indep}F \text{ in WKY rats})/(1/Na^{+}\text{total}F/Na^{+}\text{indep}F \text{ in SHR} = 1.03) \). Thus, reduced overall transport of L-carnitine in RAECs from SHR could be mainly due to reduced expression of the \( Na^+\)-dependent Octn2 in a less extend to a reduced expression of the \( Na^+\)-independent Octn1 membrane transporters. In fact, the Octn2 mRNA expression in cells from SHR is only \( 2.6 \) fold compared with Octn1 mRNA expression, a value that is largely minor compared with the \( 31 \) fold increase for this mRNA detected in cells from non-hypertensive rats. Thus, a reduced Octn2 expression without alterations in the \( V_{\text{max}}/K_m \) could account for the reduced \( TSC^+Na^{+}_{dep} \) component of L-carnitine transport in RAECs from SHR.

### Acknowledgments

The authors thank Mrs Ninoska Muñoz and Mrs Amparo Pacheco from the Cellular and Molecular Physiology Laboratory (CMPL) at the Pontificia Universidad Católica de Chile for their valuable secretarial and technical assistance, respectively.

### Author Contributions

Conceived and designed the experiments: AM CV LS. Performed the experiments: EG-G RS CS FP SZ AJB MVR-A PA AL. Analyzed the data: EG-G RS AL AM CV LS. Contributed reagents/materials/analysis tools: AL CV LS. Wrote the paper: RS EG-G CV LS.

### References

1. Melander O (2001) Genetic factors in hypertension—what is known and what does it mean? Blood Press 10: 254–270.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) ESH/ESC 2007 Guidelines for the management of arterial hypertension. Rev Esp Cardiol 60: 968–994.
3. Arduini A, Bonomi M, Savica V, Amato A, Zammit V (2008) Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 120: 149–156.
4. Ruggeri P, Cattaneo D, Loriga G, Ledda F, Motterlini N, et al. (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension 54: 567–574.

---

**Table 2.** Half-maximal effect of extracellular pH on saturable transport of L-carnitine in RAECs.

| Condition | \( SE_{50} \) (pH, units) | \( IE_{50} \) (pH, units) |
|-----------|----------------|----------------|
| WKY       |                 |                   |
| Total     | 7.73 ± 0.25     | ni                |
| \( Na^+\) _indep_ | 7.47 ± 0.11*   | ni                |
| \( Na^+\) _indep_ | ns            | 7.23 ± 0.14       |
| SHR       |                 |                   |
| Total     | ns              | 7.95 ± 0.13       |
| \( Na^+\) _indep_ | ns            | ni                |
| \( Na^+\) _indep_ | 8.10 ± 0.09    |                   |

Total transport of L-carnitine, and the \( Na^+\)-dependent (\( Na^+\) _indep_ ) and \( Na^+\)-independent (\( Na^+\) _indep_ ) transport components (20 \( \mu l/l \) L-carnitine, 3 \( \mu g/ml \) L-carnitine, 30 seconds, 37°C) in RAECs cultures from WKY rats or SHR exposed to culture medium with the pH adjusted to different values extracellular pH (pH, 5.5–8.5) as described in Methods. The stimulatory \( (SE_{50}) \) or inhibitory \( (IE_{50}) \) effect of pH on transport was calculated. ni, not inhibited; ns, not stimulated. *P<0.05 versus Total in WKY rats. Values are mean ± SEM (n=12).

doi:10.1371/journal.pone.0090339.t002

Interestingly, as found in cells from non-hypertensive rats, the relative contribution of the \( TSC^+Na^{+}_{dep} \) component to the \( V_{\max}/K_m \) for \( TSC \) was \( \sim 30\% \). Thus, a proportional change by Octn2 expression to \( (\sim 1.40 \) fold) would sustain the \( TSC^+Na^{+}_{dep} \) component of the saturable transport activity in RAECs from SHR. Interestingly, this value is \( \sim 85\% \) lower compared with the potential requested change in Octn2 mRNA expression in cells from non-hypertensive rats. Therefore, SHR is a pathological condition that results in lower request of Octn2 mRNA expression compared with RAECs from non-hypertensive rats. The results also show that L-carnitine transport in RAECs from SHR was dependent on the pH, supporting the possibility that transport was mediated by Octn1/2 in this cell type. In this case, alkalization of the extracellular medium resulted in reduced \( TSC \), which was due to reduced \( Na^+\) _indep_ component. This finding is different from RAECs from non-hypertensive rats, suggesting that alkalization could result in a differential down-regulation of L-carnitine transport in RAECs from SHR compared with non-hypertensive rats. However, since the \( Na^+\) _indep_ component of transport was also reduced in cells from non-hypertensive rats, it is likely that sensitivity of this component to a change in the pH is similar in cells from SHR and WKY rats.

In conclusion, the kinetic parameters of L-carnitine transport in RAECs from SHR and non-hypertensive WKY rats were characterized. The overall saturable transport was mediated by \( Na^+\) _indep_ and \( Na^+\)-dep components, with the latter being crucial in the reduced maximal transport capacity detected in cells from SHR. The kinetic parameters, pH, and \( Na^+\)-dependency of transport suggest that Octn1 and Octn2 are likely responsible for membrane transport of L-carnitine in endothelial cells from the aorta of SHR and WKY rats. These results are the first characterizing the kinetic parameters for the membrane transport mechanisms of L-carnitine in rat aortic endothelium from non-hypertensive WKY and spontaneously hypertensive rats. Furthermore, since (a) the reactivity of aortic rings to the endothelium-dependent vasodilator CGRP was reduced in preparations from SHR compared with WKY rats, (b) L-carnitine supplementation in vitro restored CGRP vasodilation to values in vessels from normotensive rats, and (c) CGRP was ineffective in endothelium-denuded rat aortic rings, it is suggested that restoration of a functional endothelium could result from bioavailability of L-carnitine to the aorta endothelium in the spontaneously hypertensive animals.
5. Rajasekar P, Palaniyam N, Anuradha CV (2007) Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp Hypertens 29: 517–530.

6. Furuchi Y, Sugita T, Kato Y, Shimada Y, Masuda K (2010) OCTN2 is associated with carnitine transport capacity of rat skeletal muscles. Acta Physiol 200: 57–64.

7. McCarty MF (2004) A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the antihypertensive impact of very-low-fat diets. Med Hypotheses 62: 62–71.

8. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, et al. (2008) The role of inflammatory markers in the cardio-protective effect of L-carnitine in L-NMMA-induced hypertension. Am J Hypertens 21: 1231–1237.

9. Gómez-Amores L, Mate A, Miguel-Carrasco JL, Jiménez L, Jos A, et al. (2007) L-Carnitine attenuates oxidative stress in hypertensive rats. J Nutr Biochem 18: 573–549.

10. Sharma S, Aramburu A, Rafikov R, Sun X, Kumar S, et al. (2013) L-Carnitine preserves endothelial function in a lamb model of increased pulmonary blood flow. Pediatr Res 74: 39–47.

11. Volek JS, Juletele DA, Silvestre R, Yamamoto LM, Spiering BA, et al. (2008) Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults. Am J Cardiol 102: 1413–1417.

12. Tamai I (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and SLC22A21). Biopharm Drug Diapos 34: 29–44.

13. Yabuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, et al. (1999) Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 289: 768–773.

14. Gründemann D, Harlinger S, Golz S, Geerts A, Lazar A, et al. (2005) Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102: 5256–5261.

15. Me JX, Shi NJ, Zhang Q, Gong T, Sun X, et al. (2011) Synthesis, transport and mechanism of a type 1 produg: L-carnitine ester of prednisolone. Mol Pharm 8: 1629–1640.

16. Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, et al. (2000) Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem 275: 40064–40072.

17. Enomoto A, Wempe MF, Tsachila H, Shin HJ, Cha SH, et al. (2002) Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 277: 36262–36271.

18. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmacol Rev 24: 1227–1251.

19. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34: 413–455.

20. Devos R, Boyd CA (1998) Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78: 487–545.

21. Mann GE, Yuilewich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183–252.

22. Ishihara Y, Kato Y, Watanabe T, Kohno Y, Kubo Y, et al. (2008) Involvement of carnitine/carnitine transporter OCTN2 in Alzheimer’s disease. J Biol Chem 283: 34457–34464.

23. Urban TJ, Yang C, Lagpacan LL, Brown C, Castro RA, et al. (2007) Functional characterization of organic cation/carnitine transporter family in functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Pharmacol Exp Ther 290: 1402–1409.

24. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, et al. (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. J Biol Chem 274: 33380–33392.

25. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, et al. (1999) Functional identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 277: 36262–36271.

26. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arévalo M, et al. (2013) L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPARγ expression. Biochem Pharmacol 85: 937–944.

27. Oza NB, Schwartz JH, Gould HD, Levinsky NG (1990) Rat aortic smooth muscle cells in culture express kalikrein, kininogen, and bradykininase activity. J Clin Invest 85: 597–600.

28. Guzmán-Gutiérrez E, Westmeier F, Salomón G, González M, Pardo F, et al. (2012) Insulin-increased L-arginine transport requires A2A adenosine receptors activation in human umbilical vein endothelium. PLoS One 7: e41705.

29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. Methods 25: 402–408.

30. Kanaikawala S, Pestereva E, Cheeraw G, Gupta SK, Amsar S, et al. (2012) PPARY agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. PLoS One 7: e56500.

31. Mels CM, Schutte AE, Eramus H, Huisman HW, Schutte R, et al. (2013) L-Carnitine and long-chain acylcarnitines are positively correlated with ambulatory blood pressure in humans: the SABPA study. Lipids 48: 63–73.

32. Tamai I, Yabuchi H, Nezu J, et al. (1997) Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419: 107–111.

33. Narin KR, Prasad PD, Umaphathy NS, Ganapathy V, Shekhassat PS (2007) Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+) Am J Physiol 293: G1046–G1053.

34. Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmacol Rev 24: 1227–1251.

35. Koepsell H (2013) The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34: 413–455.

36. Devos R, Boyd CA (1998) Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 78: 487–545.

37. Mann GE, Yuilewich DL, Sobrevia L (2003) Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83: 183–252.

38. Ishihara Y, Kato Y, Watanabe T, Kohno Y, Kubo Y, et al. (2008) Involvement of carnitine/carnitine transporter OCTN2 in Alzheimer’s disease. J Biol Chem 283: 34457–34464.

39. Urban TJ, Yang C, Lagpacan LL, Brown C, Castro RA, et al. (2007) Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 17: 773–782.

40. Grube M, Meyer zu Schwabedissen HE, Prager D, Haney J, Moritz KU, et al. (2006) Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 113: 1114–1122.

41. Foster KA, O'Rourke B, Reibel DK (1985) Altered carnitine metabolism in spontaneously hypertensive rats. Am J Physiol 249: 183–186.

42. Sherman DB, Calvert DT, Backwell FR, Boyd CA (1998) Peptide aminonitrogen transport by the lactating rat mammary gland. Biochim Biophys Acta 1373: 252–260.

43. Wu X, Prasad PD, Leibach FH, Ganapathy V (1998) cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 246: 509–515.

44. Aravena C, Beltrán AR, Cornejo M, Torres V, Diaz ES, et al. (2012) Potential role of sodium-proton exchangers in the low concentration arsenic trioxide-increased intracellular pH and cell proliferation. PLoS One 7: e51451.